Rational Design of Adenylation Enzyme Inhibitors

腺苷酸化酶抑制剂的合理设计

• 批准号: 8675862
• 负责人: DEREK S TAN
• 金额: $ 44.03万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-01 至 2016-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8675862
• 关键词: Active Sites; Address; Amides; Amino Acids; Amino Acyl-tRNA Synthetases; Anabolism; Anhydrides; Anti-Bacterial Agents; Bacteria; Binding; Biochemistry; Biological; Biological Factors; Biological Process; Cancer Biology; Carboxylic Acids; Cardiovascular Diseases; Cardiovascular system; Catalysis; Cells; Chemicals; Clinical Trials; Coenzyme A Ligases; Communicable Diseases; Complex; Development; Electron Transport; Enzymatic Biochemistry; Enzyme Inhibitor Drugs; Enzyme Inhibitors; Enzymes; Esters; Fatty Acids; Glycolipids; Goals; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Individual; Interdisciplinary Study; Life; Lysine; Malignant Neoplasms; Mediating; Metabolic; Metabolic Diseases; Metabolism; Microbiology; Molecular; Molecular Conformation; Mupirocin; Mycobacterium tuberculosis; Nature; Neurodegenerative Disorders; Nucleic Acid-Independent Peptide Biosynthesis; Organic Synthesis; Pathway interactions; Peptides; Permeability; Pharmaceutical Chemistry; Pharmacology; Phase; Play; Process; Property; Proteins; Quinones; Reaction; Research; Role; Siderophores; Staphylococcus aureus; Structure; Structure-Activity Relationship; Text; Therapeutic; Topical Antibiotic; Translations; Ubiquitin; Ubiquitination; Variant; Virulence Factors; Vitamin K 2; Work; acyl group; adenylate; analog; ascamycin; base; cancer therapy; design; drug discovery; immunopathology; infectious disease treatment; inhibitor/antagonist; insight; interest; methicillin resistant Staphylococcus aureus; new therapeutic target; novel; peptide synthase; preclinical evaluation; programs; protein folding; protein function; small molecule; structural biology; thioester; uptake

DESCRIPTION (provided by applicant): Rational Design of Adenylation Enzyme Inhibitors Adenylation enzymes play central roles in diverse biological pathways across all three domains of life, mediating processes such as protein translation, fatty acid and amino acid metabolism, natural product biosynthesis, and ubiquitin conjugation. These enzymes catalyze a two-step reaction involving initial ATP- dependent adenylation of a carboxylic acid substrate to form a tightly-bound acyl-AMP (acyl adenylate) intermediate, followed by attack of a nucleophile on this mixed anhydride to form an ester, thioester, or amide product. Strikingly, while all adenylation enzymes catalyze this same general reaction, at least six distinct protein folds have been identified within this mechanistic superfamily. Inhibitors of adenylation enzymes have important potential biomedical applications in infectious diseases, cancer, cardiovascular disease, metabolic disease, immunopathologies, and neurodegenerative disorders. We propose herein to continue our successful, long-term program on the rational design of adenylation enzyme inhibitors. We are advancing an inhibitor design platform that leverages mechanistic and structural information and is general for all classes of adenylation enzymes. Our previous efforts have yielded novel antibacterials targeting bacterial siderophore, glycolipid, and menaquinone biosynthesis. We have also developed semisynthetic protein inhibitors of ubiquitin/ubiquitin-like modifier E1 activating enzymes that have provided profound mechanistic insights into the functions of these enzymes. Our goals for the next project period are to develop selective inhibitors of non-ribosomal peptide biosynthesis using a macrocyclic design, to develop optimized menaquinone biosynthesis inhibitors as new antibacterials, and to develop protein-based and small-molecule inhibitors of E1 activating enzymes to probe their molecular mechanisms and biological functions in cancer. Systematic correlation of physicochemical properties with bacterial uptake will also be studied. This work will have broad impacts in structure-based design, antibacterial medicinal chemistry, and enzymology, and will be carried out through established multidisciplinary collaborations comprising combined expertise in organic synthesis, medicinal chemistry, pharmacology, biochemistry, microbiology, and structural biology.

描述（由申请人提供）：腺苷化酶抑制剂的合理设计腺苷化酶在生命所有三个领域的多种生物途径中发挥核心作用，介导蛋白质翻译、脂肪酸和氨基酸代谢、天然产物生物合成和泛素偶联等过程。这些酶催化一个两步反应，包括最初的ATP依赖的羧酸底物的腺苷化，形成紧密结合的酰基-腺苷酸中间体，然后是亲核试剂对混合酸酐的攻击，形成酯、硫酯或酰胺产物。引人注目的是，虽然所有的腺苷化酶都催化相同的一般反应，但在这个机械超家族中至少发现了六种不同的蛋白质折叠。腺苷化酶抑制剂在感染性疾病、癌症、心血管疾病、代谢疾病、免疫病理和神经退行性疾病中具有重要的潜在生物医学应用。我们在此建议继续我们成功的长期计划，合理设计腺苷化酶抑制剂。我们正在推进一种抑制剂设计平台，利用机制和结构信息，适用于所有类别的腺苷化酶。我们之前的努力已经产生了针对细菌铁载体、糖脂和甲基萘醌生物合成的新型抗菌药物。我们还开发了泛素/泛素样修饰物E1激活酶的半合成蛋白抑制剂，为这些酶的功能提供了深刻的机制见解。我们的下一个项目目标是利用大环设计开发非核糖体肽生物合成的选择性抑制剂，开发优化的甲基萘醌生物合成抑制剂作为新的抗菌药物，以及开发基于蛋白质和小分子的E1激活酶抑制剂，以探索其在癌症中的分子机制和生物学功能。理化性质与细菌摄取的系统相关性也将被研究。这项工作将对基于结构的设计、抗菌药物化学和酶学产生广泛的影响，并将通过建立多学科合作来进行，包括有机合成、药物化学、药理学、生物化学、微生物学和结构生物学方面的综合专业知识。